Trinity Biotech PLC (NASDAQ:TRIB – Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 31,360 shares, an increase of 75.5% from the September 30th total of 17,870 shares. Currently, 4.2% of the company’s shares are sold short. Based on an average daily trading volume, of 18,896 shares, the short-interest ratio is currently 1.7 days.
Hedge Funds Weigh In On Trinity Biotech
An institutional investor recently bought a new position in Trinity Biotech stock. Yorkville Advisors Global LP bought a new stake in Trinity Biotech PLC (NASDAQ:TRIB – Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 225,000 shares of the company’s stock, valued at approximately $122,000. Yorkville Advisors Global LP owned about 6.27% of Trinity Biotech at the end of the most recent reporting period. 78.97% of the stock is owned by institutional investors.
Trinity Biotech Trading Up 4.6%
Shares of NASDAQ TRIB opened at $6.55 on Tuesday. The firm’s 50-day moving average price is $7.61 and its 200-day moving average price is $15.44. Trinity Biotech has a 1-year low of $5.01 and a 1-year high of $52.50.
Wall Street Analyst Weigh In
Separately, Weiss Ratings lowered Trinity Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 4th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
Check Out Our Latest Stock Report on TRIB
About Trinity Biotech
Trinity Biotech plc is a medical diagnostics company headquartered in Dublin, Ireland, and listed on the Nasdaq under the symbol TRIB. The company develops, manufactures and markets diagnostic products used by clinical laboratories, hospitals, physicians and other healthcare providers.
Its product portfolio has historically focused on infectious disease testing, including assays for HIV and other conditions, as well as clinical chemistry, autoimmune disease and diabetes-related diagnostics.
See Also
- Five stocks we like better than Trinity Biotech
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
